Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/10931
In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens
StatisticsItem usage statistics
MetadataShow Dublin Core item record
AuthorBlasco, Lucia; Ambroa, Anton; Trastoy, Rocio; Bleriot, Ines; Moscoso, Miriam; Fernandez-Garcia, Laura; Perez-Nadales, Elena; Fernandez-Cuenca, Felipe; Torre-Cisneros, Julian; Oteo-Iglesias, Jesus; Oliver, Antonio ; Canton, Rafael; Kidd, Tim; Navarro, Ferran; Miro, Elisenda; Pascual, Alvaro; Bou, German; Martinez-Martinez, Luis; Tomas, Maria
Document typeresearch article
CitationBlasco L, Ambroa A, Trastoy R, Bleriot I, Moscoso M, Fernandez-Garcia L, et al. In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens. Sci Rep. 2020 Apr 28;10(1):7163.
The emergence of multidrug resistant (MDR) pathogenic bacteria is jeopardizing the value of antimicrobials, which had previously changed the course of medical science. In this study, we identified endolysins ElyA1 and ElyA2 (GH108-PG3 family), present in the genome of bacteriophages Ab1051 Phi and Ab1052 Phi, respectively. The muralytic activity of these endolysins against MDR clinical isolates (Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae) was tested using the turbidity reduction assay. Minimal inhibitory concentrations (MICs) of endolysin, colistin and a combination of endolysin and colistin were determined, and the antimicrobial activity of each treatment was confirmed by time kill curves. Endolysin ElyA1 displayed activity against all 25 strains of A. baumannii and P. aeruginosa tested and against 13 out of 17 strains of K. pneumoniae. Endolysin ElyA2 did not display any such activity. The combined antimicrobial activity of colistin and ElyA1 yielded a reduction in the colistin MIC for all strains studied, except K. pneumoniae. These results were confirmed in vivo in G. mellonella survival assays and in murine skin and lung infection models. In conclusion, combining colistin (1/4 MIC) with the new endolysin ElyA1 (350 mu g) enhanced the bactericidal activity of colistin in both in vitro and in vivo studies. This will potentially enable reduction of the dose of colistin used in clinical practice.
resistencia a medicamentos
pruebas de sensibilidad microbiana
This item appears in following Docusalut collectionsHospital Universitario Son Espases - HUSE > Comunicación científica
Instituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científica